Niedrig et al.; Inhibition of infectious human immunodeficiency virus . . . ; J. Gen. Vir.; 75; pp. 1469-1474, 1994.* |
Massiah et al; Three-dimensional structure of the human immunodeficiency virus . . . ; J. Mol. Vir.; 244; pp. 198-223, 1994.* |
Neidrig, “Inhibition of infectious human immunodeficiency Virus type 1 particle formation Gag prote-derived peptides”, Journal of General Virology, vol. 75, 1994, pp. 1469-1474. |
Matthews et al, “Refined solution structure of p17, the HIV matrix protein” Biochemical Society Transactions, vol. 23, No. 4, Nov. 1995, pp. 725-729. |
Massiah et al, “Three-dimensional structure of the Human Immunideficiency Virus type 1 matrix protein” Journal of Molecular Biology, vol. 244, No. 2, 1994, pp. 198-223. |
Cannon et al, “Murine Leukemia Virus-based tat-inducible Long Terminal Repeat repalcement vectors: a new system for anti-Human Immunodeficiency Virus gene therapy”, Journal of Virology, vol. 70, No. 11, Nov. 1996, pp. 8234-8240. |
Matthews et al, “Structural similarity between the p17 matrix protein of HIV-1 and interferon”, Nature, vol. 370, No. 6491, Aug. 25 1994, pp. 666-668. |
Cornelissen et al,“Human Immunideficiency Virus type 1 subtypes defined by env show high frequency of recombinant gag genes”, Journal of Virology, vol 70, No. 11, Nov. 1996, pp. 8209-8212. |
Cannon et al, “Structure-function studies of the Human Immunodeficiency Virus type 1 matrix protein p17”, Journal of Virology, vol. 71, No. 5, May 1997, pp. 3474-3483. |